A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand.
Identifieur interne : 000112 ( PubMed/Corpus ); précédent : 000111; suivant : 000113A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand.
Auteurs : Punnee Pitisuttithum ; Ponthip WirachwongSource :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2019.
English descriptors
- KwdEn :
- Antibodies, Viral (immunology), Epidemics (prevention & control), Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H5N2 Subtype, Influenza Vaccines (immunology), Influenza, Human (prevention & control), Security Measures, Thailand, Vaccines, Attenuated (immunology), Vaccines, Inactivated (immunology).
- MESH :
- chemical , immunology : Antibodies, Viral, Influenza Vaccines, Vaccines, Attenuated, Vaccines, Inactivated.
- geographic : Thailand.
- prevention & control : Epidemics, Influenza, Human.
- Humans, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H5N2 Subtype, Security Measures.
Abstract
Being vigilant of the potential for an influenza pandemic, the Global Action Plan for Influenza Vaccines (GAP) promoted the establishment and maintenance of local vaccine manufacturing capacity. In accordance with this, the Thai government has developed its national strategic plan for influenza pandemic preparedness including the plan for manufacturing influenza vaccine in Thailand. With the support of WHO, the Thai Government Pharmaceutical Organization (GPO) as the developed local production capacity of influenza vaccines. The H1N1 live attenuated influenza vaccine (LAIV) and H5N2 LAIV produced by GPO have been proven to be safe and immunogenic through clinical trials, followed by Thai FDA licensure for pandemic use. The GPO-produced H5N2 LAIV has been proven to have priming effects on an inactivated subunit H5N1 booster vaccine. This Thai local manufacturer is now expanding its capacity to Inactivated Influenza Vaccine (IIV), aiming for sustainable influenza vaccine production for national coverage.
DOI: 10.1080/21645515.2019.1638205
PubMed: 31335234
Links to Exploration step
pubmed:31335234Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand.</title><author><name sortKey="Pitisuttithum, Punnee" sort="Pitisuttithum, Punnee" uniqKey="Pitisuttithum P" first="Punnee" last="Pitisuttithum">Punnee Pitisuttithum</name><affiliation><nlm:affiliation>Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University , Bangkok , Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Wirachwong, Ponthip" sort="Wirachwong, Ponthip" uniqKey="Wirachwong P" first="Ponthip" last="Wirachwong">Ponthip Wirachwong</name><affiliation><nlm:affiliation>Research and Development Institute, Government Pharmaceutical Organization , Bangkok , Thailand.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31335234</idno><idno type="pmid">31335234</idno><idno type="doi">10.1080/21645515.2019.1638205</idno><idno type="wicri:Area/PubMed/Corpus">000112</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000112</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand.</title><author><name sortKey="Pitisuttithum, Punnee" sort="Pitisuttithum, Punnee" uniqKey="Pitisuttithum P" first="Punnee" last="Pitisuttithum">Punnee Pitisuttithum</name><affiliation><nlm:affiliation>Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University , Bangkok , Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Wirachwong, Ponthip" sort="Wirachwong, Ponthip" uniqKey="Wirachwong P" first="Ponthip" last="Wirachwong">Ponthip Wirachwong</name><affiliation><nlm:affiliation>Research and Development Institute, Government Pharmaceutical Organization , Bangkok , Thailand.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Viral (immunology)</term><term>Epidemics (prevention & control)</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H5N2 Subtype</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Security Measures</term><term>Thailand</term><term>Vaccines, Attenuated (immunology)</term><term>Vaccines, Inactivated (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Thailand</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Epidemics</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H5N2 Subtype</term><term>Security Measures</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Being vigilant of the potential for an influenza pandemic, the Global Action Plan for Influenza Vaccines (GAP) promoted the establishment and maintenance of local vaccine manufacturing capacity. In accordance with this, the Thai government has developed its national strategic plan for influenza pandemic preparedness including the plan for manufacturing influenza vaccine in Thailand. With the support of WHO, the Thai Government Pharmaceutical Organization (GPO) as the developed local production capacity of influenza vaccines. The H1N1 live attenuated influenza vaccine (LAIV) and H5N2 LAIV produced by GPO have been proven to be safe and immunogenic through clinical trials, followed by Thai FDA licensure for pandemic use. The GPO-produced H5N2 LAIV has been proven to have priming effects on an inactivated subunit H5N1 booster vaccine. This Thai local manufacturer is now expanding its capacity to Inactivated Influenza Vaccine (IIV), aiming for sustainable influenza vaccine production for national coverage.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31335234</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>10</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand.</ArticleTitle><Pagination><MedlinePgn>2440-2445</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2019.1638205</ELocationID><Abstract><AbstractText>Being vigilant of the potential for an influenza pandemic, the Global Action Plan for Influenza Vaccines (GAP) promoted the establishment and maintenance of local vaccine manufacturing capacity. In accordance with this, the Thai government has developed its national strategic plan for influenza pandemic preparedness including the plan for manufacturing influenza vaccine in Thailand. With the support of WHO, the Thai Government Pharmaceutical Organization (GPO) as the developed local production capacity of influenza vaccines. The H1N1 live attenuated influenza vaccine (LAIV) and H5N2 LAIV produced by GPO have been proven to be safe and immunogenic through clinical trials, followed by Thai FDA licensure for pandemic use. The GPO-produced H5N2 LAIV has been proven to have priming effects on an inactivated subunit H5N1 booster vaccine. This Thai local manufacturer is now expanding its capacity to Inactivated Influenza Vaccine (IIV), aiming for sustainable influenza vaccine production for national coverage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pitisuttithum</LastName><ForeName>Punnee</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-3215-2183</Identifier><AffiliationInfo><Affiliation>Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University , Bangkok , Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wirachwong</LastName><ForeName>Ponthip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research and Development Institute, Government Pharmaceutical Organization , Bangkok , Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058872" MajorTopicYN="N">Epidemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053125" MajorTopicYN="N">Influenza A Virus, H5N2 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012637" MajorTopicYN="Y">Security Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013785" MajorTopicYN="N" Type="Geographic">Thailand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Influenza vaccine</Keyword><Keyword MajorTopicYN="Y">live attenuated</Keyword><Keyword MajorTopicYN="Y">national security</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31335234</ArticleId><ArticleId IdType="doi">10.1080/21645515.2019.1638205</ArticleId><ArticleId IdType="pmc">PMC6816430</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2013 Mar 1;31(11):1503-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23318149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2017 Aug;17(8):833-842</Citation><ArticleIdList><ArticleId IdType="pubmed">28533093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2014 Jun 15;209(12):1860-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24604819</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Jul 1;29 Suppl 1:A29-33</Citation><ArticleIdList><ArticleId IdType="pubmed">21684425</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 1986 Jan;23(1):66-72</Citation><ArticleIdList><ArticleId IdType="pubmed">3700610</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2014 Sep 15;210(6):865-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24676204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000112 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000112 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:31335234
|texte= A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:31335234" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |